Arrowhead Pharmaceuticals (NASDAQ:ARWR) is set to issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.22 per share for the quarter.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, February 7th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.63). The company had revenue of $34.66 million for the quarter, compared to analyst estimates of $90.88 million. Arrowhead Pharmaceuticals had a negative net margin of 61.78% and a negative return on equity of 24.23%. On average, analysts expect Arrowhead Pharmaceuticals to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
ARWR stock opened at $18.55 on Tuesday. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of -28.54 and a beta of 2.15. Arrowhead Pharmaceuticals has a 52-week low of $7.17 and a 52-week high of $22.39.
In related news, COO Bruce D. Given sold 242,834 shares of the company’s stock in a transaction that occurred on Tuesday, February 12th. The stock was sold at an average price of $16.04, for a total value of $3,895,057.36. Following the transaction, the chief operating officer now owns 859,523 shares in the company, valued at $13,786,748.92. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Bruce D. Given sold 46,167 shares of the company’s stock in a transaction that occurred on Friday, February 8th. The shares were sold at an average price of $15.34, for a total value of $708,201.78. Following the completion of the transaction, the chief operating officer now owns 859,523 shares in the company, valued at approximately $13,185,082.82. The disclosure for this sale can be found here. Insiders sold a total of 595,001 shares of company stock worth $10,365,597 in the last 90 days. Company insiders own 4.80% of the company’s stock.
ARWR has been the subject of a number of analyst reports. Chardan Capital reiterated a “buy” rating and set a $24.50 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, February 11th. BidaskClub upgraded Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, February 14th. Cantor Fitzgerald set a $24.00 target price on Arrowhead Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, April 12th. Finally, Piper Jaffray Companies boosted their target price on Arrowhead Pharmaceuticals from $25.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 16th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Arrowhead Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $22.70.
ILLEGAL ACTIVITY WARNING: This piece was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2019/05/07/arrowhead-pharmaceuticals-arwr-scheduled-to-post-earnings-on-wednesday.html.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Read More: What Factors Can Affect Return on Equity?
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.